EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor
EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. …